China News Service, Shanghai, August 4 (Reporter Chen Jing) The reporter learned on the 4th that the liver surgery team of Fudan University Tumor Hospital has successfully drawn a "gene map" of intrahepatic cholangiocarcinoma based on the Chinese population, revealing its gene mutation characteristics.
This large-scale genomics study aimed at a large population of intrahepatic cholangiocarcinoma is the first to provide basic data for the formulation of targeted therapy and immunotherapy for Chinese patients with intrahepatic cholangiocarcinoma. Related research is published in the international authoritative journal "Journal of Translational Medicine".
In the human digestive system, the bile produced by liver cells flows out and converges through the bile ducts in the liver, reaches through the common bile duct and is stored in the gallbladder. Intrahepatic cholangiocarcinoma is the cancerous transformation of the bile duct in the liver, and its incidence is related to factors such as hepatitis virus, liver fluke infection and intrahepatic bile duct stones. This is one of the common primary malignant tumors of the liver.
Professor Wang Lu, director of the liver surgery department of Fudan University Cancer Hospital and chief expert of the multidisciplinary comprehensive diagnosis and treatment team of liver tumors, said in an interview that because intrahepatic cholangiocarcinoma has no specific symptoms in the early stage, 65% of patients are in the advanced stage when they show symptoms. .
It is reported that surgery is currently the most effective means of radical treatment of intrahepatic cholangiocarcinoma. Those who miss radical surgery have a 5-year survival rate of less than 20% through radiotherapy, chemotherapy or palliative treatment. Professor Wang Lu told reporters that there are very limited treatment options for patients with intrahepatic cholangiocarcinoma who are late or cannot undergo surgery.
It is understood that at present, there are few large-scale genomics studies using second-generation gene sequencing technology for intrahepatic cholangiocarcinoma in the Chinese population, which greatly restricts the implementation of precise methods such as targeted therapy and immunotherapy. The research team used this technology to sequence genes from a large number of patients’ tissue samples and analyze the characteristics of gene mutations to draw a "gene map" of bile duct cancer in China.
Wang Lu said: "Finding the gene mutation site means that it is possible to find the corresponding'targeted therapy'. The results of large-scale gene sequencing have guided the classification and treatment of intrahepatic cholangiocarcinoma." (End)